We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
An Indian trial evaluating convalescent plasma as a COVID-19 treatment has found that the therapy failed to reduce progression to severe COVID-19 or death, leaving the Indian government skeptical about its viability, though medical experts say the treatment may still hold promise. Read More
CRISPR Therapeutics has reported positive results for a phase 1 study evaluating CTX110, its chimeric antigen receptor (CAR) T-cell therapy for the treatment of relapsed or refractory nonHodgkin’s lymphoma in patients who have received at least two prior lines of therapy. Read More
Adicet has won Investigational New Drug clearance from the FDA for ADI-001, a chimeric antigen receptor (CAR) gamma delta T-cell therapy for nonHodgkin’s lymphoma. Read More
Roche and Atea Pharmaceuticals have struck a deal to develop a COVID-19 antiviral pill, AT-527, currently being evaluated in a phase 2 study. Read More
Dr. Reddy’s Laboratories, one of India’s largest pharmaceutical companies, announced Thursday that it has temporarily shut down all of its data center services in response to a cyberattack. Read More
AstraZeneca’s COVID-19 vaccine candidate, AZD1222, currently being evaluated in phase 3 global trials, delivers a strong immune response, according to a new UK study. Read More
The COVID-19 pandemic is worsening a pre-existing problem of drug shortages in the U.S., University of Minnesota researchers report in a new analysis. Read More
The FDA’s Vaccines and Related Biological Products Advisory Committee took no action Thursday after a lengthy discussion of the agency’s COVID-19 vaccine requirements, considerations for continuing blinded phase 3 trials after an Emergency Use Authorization (EUA) is issued and postmarket studies. Read More